CVS Health, Walgreens hit with FDA warning letter
Justin Sullivan

Editor's note: This article was updated at 1245p ET to include Walgreens Boots as a warning letter recipient.

The US FDA has issued CVS Health (NYSE:CVS) and Walgreens Boots Alliance (NASDAQ:WBA) with formal warning letters over the sale of some of the companies' OTC eye relief drops.

The agency contends that CVS pink eye relief drops are an unapproved new drug product. It added that the labeling of the product claims to relieve excessive watery discharge, sensation of grittiness, and redness and burning
Although CVS Health (CVS) bills the treatment as a homeopathic remedy, the FDA says it is still subject to the same requirements as other drugs.

The letter, dated Sept. 11, asks for a response on actions taken within 15 working days.
The FDA's letter to Walgreens Boots (WBA) takes aim at three products, for allergy, stye, and pink eye drops. It also asks for a reply in 15 working days.


More on CVS Health

CVS Health upgraded at Wolfe citing near-term turnaround
CVS Health: Share Price Suffers As Business Transformation Flounders
CVS Health: Blue Shield Runs To Amazon, But Valuation Still Makes Sense
Walgreens Vs. CVS: I Call A Tie Now Based On A Peter Lynch Evaluation
CVS: In Search Of A Major Low
Seeking Alphaâs Quant Rating on CVS Health